Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06742892 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy

Name: A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy — clinical trial record (NCT06742892)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorShanghai Henlius Biotech

Started2025-03-03

View on ClinicalTrials.gov ↗

Amendment history

2025-03-05

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-02-15→confirmed 2025-03-03

Study sites0→1

2024-12-16

Original filing

Shanghai Henlius Biotech

56 trials monitored

See all monitored trials

Liver Cancer

1,505 trials monitored

See 60 trials at risk

The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Failed or Intolerance to Standard Therapy

Trial Details

NCT Number	NCT06742892
Lead Sponsor	Shanghai Henlius Biotech
Conditions	Carcinoma, Hepatocellular
Enrollment	90 participants
Start Date	2025-03-03
Primary Completion	2026-10-31 (estimated)
Study Completion	2027-06-05 (estimated)
Updated on ClinicalTrials.gov	2025-03-10